GlassScriptPhysician profile
Hartmut Uschmann
NPI 1972517308
$650.61
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $94.49 · 2021: $120 · 2022: $105.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $142.09 | 2019-2022 | |
| Genzyme Corporation | $117.53 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $110.65 | 2019 | |
| Natus Medical Incorporated | $83.00 | 2022 | |
| Portola Pharmaceuticals, LLC | $42.00 | 2019 | |
| Allergan, INC. | $25.76 | 2019 | |
| Csl Behring | $23.97 | 2019 | |
| Genentech USA, INC. | $23.40 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $20.73 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.46 | 2020 | |
| Biogen, INC. | $16.94 | 2019 | |
| Chiesi USA, INC. | $13.10 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.98 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hartmut Uschmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.